A Screening Strategy for Metal Antitumor Agents as Exemplified by Gold(III) Complexes

Area of Science:

• Medicinal Chemistry
• Oncology
• Pharmacology

Background:

• Developing novel metal-based anticancer agents is crucial due to resistance to existing platinum-based drugs.
• Human tumor cell lines tumorigenic in immune-deprived mice provide a relevant model for in vitro and in vivo screening.
• Understanding the mechanism of action is key to identifying new therapeutic strategies.

Purpose of the Study:

• To evaluate the antitumor activity of novel gold(III) compounds.
• To investigate the mechanism of action of these gold(III) compounds.
• To determine if these compounds represent a new class of metal-based anticancer agents.

Main Methods:

• Screening of 2-"[(dimethylamino)-methyl]phenyl" (damp) gold(III) compounds ([Au X2(damp)]) against human tumor cell lines in vitro.
• In vivo efficacy studies using experimental animal models with HT1376 bladder and CH1 ovarian tumors.
• Comparative analysis of biochemical mechanisms against platinum-based drugs like cisplatin.

Main Results:

• All tested gold(III) compounds demonstrated selective activity against the HT1376 bladder tumor cell line in vitro.
• Compounds showed activity in an in vitro panel of ovarian tumor cell lines.
• The acetato gold(III) complex exhibited efficacy in animal models for both bladder and ovarian tumors.
• Gold(III) compounds displayed a biochemical mechanism distinct from platinum-based drugs.

Conclusions:

• The studied gold(III) compounds possess significant in vitro and in vivo antitumor activity.
• These gold(III) complexes represent a potentially new class of metal-based anticancer agents.
• Their unique mechanism of action differentiates them from established platinum-based therapies.